Skip to content
drillr.ai

ANAB

AnaptysBio, Inc.

NASDAQ · USHealthcareBiotechnology
$50.29-13.29%

Price as of Jul 20, 2026

ANAB news

AnaptysBio, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next

    Issued on behalf of Conexeu Sciences Inc. As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it RENO, Nevada, July 15, 2026 (GLOBE NEWSWIRE) -- Energy Metal News (https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=) New

    Globe Newswire ·

  2. Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

    * Strengthens Leadership Team and Board with additional business development, finance and royalty management expertise SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced the appointment of Christopher Murphy as Chief Financial Officer and Owen Hughes as a member of its Board of Directors. “We are excited to welcome Chris, who will be fully dedica

    Globe Newswire ·

  3. Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

    Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence PR Newswire WASHINGTON, April 28, 2026 WASHINGTON, April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in New England Journal of Medicine (NEJM) Evidence(1). (https://mma.prnewswire.c

    PR Newswire ·

  4. Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim

    * Ruling preserves current contracted royalty rates and rejects Tesaro’s request for any royalty reduction * Trial to adjudicate Anaptys’ contract claims and right to seek reversion of Jemperli against Tesaro/GSK is scheduled for July 14-17, 2026 SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that the Delaware Chancery Court has dismissed Te

    Globe Newswire ·

  5. Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics

    * Board sets spin-off distribution date for First Tracks Biotherapeutics: expected to occur April 20, 2026, pre-market * Stockholders will receive one share of First Tracks Bio common stock for every one share of AnaptysBio common stock owned * First Tracks Bio initial cash balance of $180 million, inclusive of $80 million from private placement SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its Board of Directors has approved the previously an

    Globe Newswire ·

  6. First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

    * Inclusive of $80 million in proceeds from private placement by leading investors * First Tracks Biotherapeutics to launch with $180 million in cash and two-year cash-runway SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its planned spin-off, First Tracks Biotherapeutics, Inc. (“First Tracks Bio”), and EcoR1 Capital (the “Selling Stockholder”) have entered into a purchase agreement with certain third-party investors for a $145 million private

    Globe Newswire ·

  7. Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results

    * Spin-off of biopharma operations into a public company to be called “First Tracks Biotherapeutics” on track for Q2 2026, potentially as early as late-April * Phase 1b enrollment ongoing in celiac disease and trial cohort initiated in eosinophilic esophagitis for ANB033, a CD122 antagonist * GSK announced strong commercial performance for Jemperli, growing >13% quarter-over-quarter to $343 million in Q4 2025, implying a ~$1.4 billion annualized run rate * Expect to achieve >$390 million in annu

    Globe Newswire ·